Delivery Order SPE2DB22D2206-SPE2DB24FJC54
Award Date
7/9/24
Potential Completion Date
7/10/24
Potential Value
$2.5K
Federal Agency
Defense Logistics Agency
Awardee
Amerisourcebergen Drug Corp
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, is for the delivery of RESTASIS 0.05% eye emulsion to the Defense Logistics Agency (DLA). The award, with a ceiling value of $2,794.50, is a firm fixed-price delivery order that will be fulfilled by December 31, 2024. The contract is not designated as a set-aside. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at $999,999,999, which serves...
This is a federal delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for RESTASIS 0.05% eye emulsion. The contract has a Firm Fixed Price of $2,160.96 and an ultimate completion date of August 20, 2024. The order is not a set-aside contract. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued up to $999,999,999 through December 2025, to provide a wide...
This federal contract award, valued at $2,745.00, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract is a Firm Fixed Price Delivery Order for the supply of RESTASIS 0.05% Eye Emulsion 30s, a prescription eye medication. The contract has an ultimate completion date of May 28, 2024. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at $999,999,999, which serves...
This federal contract award is for a delivery order to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of RESTASIS 0.05% eye emulsion. The award, valued at $1,080.48, was made by the Defense Logistics Agency (DLA) under an Indefinite Delivery Contract (IDC) with the company worth up to $999,999,999.00. This IDC, which runs through November 2026, serves as the primary vehicle for Amerisourcebergen to provide a comprehensive range of pharmaceutical products and...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of 4,558,152,346 units of RESTASIS 0.05% eye emulsion. The $8,122.89 firm fixed-price delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00 held by Amerisourcebergen's parent company, Cencora, Inc., which runs through November 2026. This IDC serves as the primary vehicle for Cencora,...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $5,818.23 firm fixed-price delivery order is for the supply of RESTASIS 0.05% eye emulsion. The contract has an ultimate completion date of May 19, 2025 and is not associated with a set-aside. Amerisourcebergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $12,948.36 firm-fixed-price delivery order contract is for the supply of RESTASIS 0.05% eye emulsion, a prescription medication used to treat dry eye disease. The contract has an ultimate completion date of October 23, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
The federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, was issued by the Defense Logistics Agency (DLA) for the supply of RESTASIS 0.05% eye emulsion. The contract, with a ceiling value of $3,657.99, is a Delivery Order under an Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical. This IDC, valued at $999,999,999, serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Restasis 0.05% eye emulsion. The contract, valued at $3,180.58, is a firm fixed-price delivery order with a completion date of November 26, 2021. This award is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen's parent company, Cencora, Inc., with the DLA Troop Support Medical, valued at up to...
This federal contract award is to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of RESTASIS 0.05% eye emulsion medication. The contract award, valued at $8,625.86, was issued by the Defense Logistics Agency (DLA) as a delivery order. The contract has a firm fixed price pricing type and an ultimate completion date of August 23, 2024. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued up to $999,999,999...